Zogenix Announces FDA Agreement to Proceed with Resubmission of FINTEPLA® NDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Zogenix, Inc. (ZGNX) PT Raised to $65 at Mizuho Securities
June 28, 2019 7:36 AM EDTMizuho Securities analyst Difei Yang raised the price target on Zogenix, Inc. (NASDAQ: ZGNX) to $65.00 (from $58.00) while maintaining a Buy rating following the FDA's decision to allow a re-submission of the NDA for FINTEPLA.
Based on final meeting minutes, the FDA... More
